

March 2017

CURRICULUM VITAE

TAIMOUR LANGAEE, MSPH, PhD

PERSONAL DATA

Office Address: Department of Pharmacotherapy and Translational Research
Center for Pharmacogenomics
University of Florida, College of Pharmacy
1600 SW Archer Road, University of Florida
Gainesville, FL 32610

E-mail: langaee@cop.ufl.edu
Langaee@gmail.com

Telephone: office-(352)273-6357
Fax- 9352)273-6121

EDUCATION

1976-1979 **Bachelor of Science (BSc)**, Microbiology
University of Texas at Arlington, Arlington, Texas, U.S.A.

1984-1987 **Master of Science (MSc)**, Microbiology
Master of Science Public Health (MSPH)
Tehran University of Medical Sciences, Tehran, Iran.

1994-1999 **PhD**, Microbiology and Immunology
Laval University, Ste-Foy, Quebec, Canada

POST-DOCTORAL TRAINING

1999-2001 *Postdoctoral Fellow*
University of McGill and Montreal
Dept. of Molecular Genetics and Immunology

2001-2002 *Postdoctoral Fellow*
University of Florida
Dept. of Molecular Genetics and Microbiology

PROFESSIONAL APPOINTMENTS

1987–1994 *Director of Quality Control Laboratory*
Bayer Pharmaceutical Corporation

Positions and Honors since 2002

2002-2007 Research Assistant Professor College of Pharmacy,
University of Florida

2008-Present Research Associate Professor College of Pharmacy,
University of Florida

2002-Present Director UF Center for Pharmacogenomics Genotyping Core
Laboratory, College of Pharmacy, University of Florida

2008-2009	NIH Warfarin Study (COAG Trial) Reference Laboratory Subcommittee
2008-2012	NIH Warfarin Study (COAG Trial) Genotyping Subcommittee
2008-2016	Consultant for UF Clinical and Translational Science Institute (CTSI) Genotyping Core
2012-2016	Director UF Clinical and Translational Science Institute (CTSI) Genotyping Core
2012-2016	NIH PGRN and Deep Sequencing Resource Network-wide RNA-Seq Project Subcommittee

PROFESSIONAL EXPERIENCE

2002-Present	<i>Research Associate Professor, Graduate Coordinator Director, University of Florida Center for Pharmacogenomics Genotyping Core Lab Dept. of Pharmacotherapy and Translational Research, College of Pharmacy, Center for Pharmacogenomics, University of Florida</i>
--------------	--

TEACHING:

Drug Metabolism, Drug Transporters, and Pharmacogenomics; PHA 6936
 Pharmacogenomics; PHA 6449 – Section 8442
 Therapeutic and Diagnostic Analysis and Pharmacogenomics; PHA 5113
 Advanced Research; PHA7979
 Doctoral Research; PHA7980
 Advanced Oral Medicine and Dental Pharmacology; DEN 6678
 Clerkship Course PHA 5663 (Cardiovascular Research)
 Interdisciplinary Family Health (IFH); BMS 6828/6829

University of Florida, College of Pharmacy

Graduate Coordinator

Advanced Practice Teaching Experience:

2003-Present	PHA 5659	Cardiovascular Research
--------------	----------	-------------------------

National Committee Member:

NIH Warfarin Study (COAG Trial) Genotyping Subcommittee,	2008-2009
NIH Warfarin Study (COAG Trial) Reference Laboratory Subcommittee,	2008-2009
NIH PGRN and Deep Sequencing Resource Networkwide RNAseq Project Subcommittee,	2011-Present
NIH PGRN Rare Genetic Variants (VIP CAPTURE PROJECT) Subcommittee,	2011-Present

University of Florida and College of Pharmacy Committee Member:

University of Florida Center for Pharmacogenomics Genotyping Core Laboratory, Director, 2002-present

University of Florida Genetics Institute, Member, 2003-present

Clinical and Translational Science Institute Genotyping Core Laboratory Consultant, 2007 to present

University of Florida, Financial Aid and Scholarship [Oct.2008-present]

University of Florida, College of Pharmacy study section for accreditation committee

University of Florida, College of Pharmacy Admission committee, 2011-Present

University of Florida (UF&Shands) Personalized Medicine Program (PMP) Stakeholder, 2012-Present

University of Florida (UF&Shands) PMP subcommittee of the Pharmacy and Therapeutic (T&P) Committee member, 2012-Present

Editorial Board

Journal of Pharmacovigilance

International Journal of Molecular and Clinical Microbiology

Reviewed Manuscripts for Journals:

Clinical Pharmacology and Therapeutics

BMC Cancer

PLOS ONE

PLOS Pathogens

Disease Marker IOS Press

Genetic Testing and Biomarkers

Biological Research for Nursing

Future Medicine

Molecular human Production

Clinical Chemistry

Psychosomatic Medicine

Biotechnology

Mutation research

BioMed central

Research in Microbiology

European Journal of Epilepsy

Pediatrics

Pharmacogenomics

Pharmacotherapy

Journal of Global Infectious Diseases

Plant Pathology

External Reviewer of Promotion and Tenure Documents

Wayne State University (College of Medicine)

ADVISING:

PharmD student Advisor

Graduate student Advisor

Faculty Advisor

SUPERVISING AND MENTORING:

Mentor for K12 Scholar

Mentor for K23 Applicant

Mentor for OAIC RCDC Scholar

Postdoctoral Fellows
Professional/Undergraduate Research Mentoring
UF Minority students

Postdoctoral Fellow and Resident Supervised:

2014-2015

Issam Hamadeh
Miguel Ramos

2013-2014

Issam Hamadeh
Teresa Vo
Ben Kong

2012-2013

Caitrin McDonough
Issam Hamadeh
Murali Munisamy

2011-2012

Alex vandell
Caitrin McDonough
Mohamed M. Islam

2010-2011

Julio Duarte

2008-2009

Yuxin Niu PhD
Micheal Pacanowski PharmD
Mohamed Shafiu MD

2007-2008

Yuxin Niu PhD
Micheal Pacanowski PharmD
Mohamed Shafiu MD

2006-2007

Luba Kielbasa, Pharm.D.
Jaekyu Shin, Pharm.D.
Micheal Pacanowski PharmD

2005-2006

Martin Brunner, M.D.
Luba Kielbasa, Pharm.D.
Jaekyu Shin, Pharm.D.
Micheal Pacanowski, Pharm.D.
Yasmeen Khan, M.D.

2004-2005

Martin Brunner, M.D.
Yan Gong, Ph.D.
Amber Beitelshees, Pharm.D.
Jaekyu Shin, Pharm.D.
Mathew Hruska, Pharm.D.
Christine Formea, Pharm.D.

2003-2004

Issam Zineh, Pharm.D.

Christina Aquilante, Pharm.D.
Amber Beitelshes, Pharm.D.
Christine Formea, Pharm.D.
Mathew Hruska, Pharm.D.

2002-2003

Issam Zineh, Pharm.D.
Christina Aquilante, Pharm.D.
Amber Beitelshes, Pharm.D.
Toya Bowles, Pharm.D.
Abdulkarim Albelkairy, Pharm.D.

Ph.D. Students mentored and supervised:

Felipe De Oliveira
Obiko Magvajav
Bradley Stockard
Eric Eggelund
Carol Sa
Basma Fouad
Mohamed Solayman
Nihal Alrouby
Mohamed Shahin
Ahmed Albassam
Marina Kawaguchi
Shin Wen Chang
Jennifer Dungan
Ann Schentrup
Mohamed Islam
Max Lobmeyer
Heather Davis
Mariellen Moore
Julio Duarte
Melonie Stanton
MiPhong Le
Hrishikish Navar

Professional/Undergraduate Research Mentoring:

2002-2017
Mentored more than 100 Undergraduate and PharmD students

2004-2014
Mentored UF-Undergraduate students from UF-Scholars Program

GRANTS AND RESEARCH:

Pending

Role: Co-Principal Investigator

PARENT STTR/[R41/R42]; 8/1/2016-8/31/2019 \$1,700,000.00
Title: Personalized Dosing of Dichloroacetate for the Treatment of Rare and Common Diseases
PI: Dr. Peter Stacpoole)

Active

Role: Principal Investigator

Research Grant 6/30/2016-5/30/ 2017 \$290,100

Canon U.S. Life Sciences

The Canon U.S. Life Sciences division has contracted with the University of Florida College of Pharmacy's Center for Pharmacogenomics to test and establish the reliability and repeatability of the DNA Analyzer genotyping platform.

PIs: Dr. Taimour Langaee/Larisa Cavallari

Role: Co-Principal Investigator

R21/R33 /NIH 6/15//2015-8/31/2019 \$2,016,800

Title: Countering Beta-lactam resistance in *Pseudomonas aeruginosa*

The aims of this study are to elucidate the molecular mechanisms of AmpG-dependent resistance against β -lactams and identify effective AmpG inhibitors for clinical application. Effective AmpG inhibitors can help us fight against β -lactam resistant pathogens while bring ineffective β -lactams to life, expanding our arsenals against the deadly bacterial infections.

PIs: Dr. Shouguang Jin; Dr. Louis Scampavia

Role: Co-Investigator

Source: NIH/NHGRI (U01 HG007269) May 2013 to April 2017 \$3,749,997

Title: Genomic Medicine Implementation: The Personalized Medicine Program

PI: Dr. Julie Johnson

Role: Co-Investigator

FDA/U01 FD005235-01 9/1/2014 to 8/31/2017 \$2,332,870

Title: Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs

The aims of this study are to compare the pharmacokinetics and cardiovascular responses to brand name and generic metoprolol ER products in patients with hypertension; to determine the impact of gastric pH variation on the concentration-response relationship with different metoprolol ER products; and to examine the effect of *CYP2D6* genotype on the pharmacokinetics of different metoprolol ER products.

MPIs: Dr. Larisa Cavallari and Dr. Julie A. Johnson

Completed Research Support**Role: Principal Investigator**

Research Grant 10/30/2014-8/30/ 2015 \$116,100

Canon U.S. Life Sciences

The Canon U.S. Life Sciences division has contracted with the University of Florida College of Pharmacy's Center for Pharmacogenomics to test and establish the reliability and repeatability of the DNA Analyzer genotyping platform.

PI: Dr. Taimour Langaee

Role: Co-Investigator

U01 GM074492 August 2010 - July 2016 \$10,724,275.00

NIH/NIGM,

Title: Pharmacogenomic Evaluation of Antihypertensive Response (PEAR-2)

This study aims to advance hypertension pharmacogenomics, focusing defining replicated genetic determinants of the antihypertensive and adverse metabolic effects of thiazide diuretics and beta-blockers, along with the genetic determinants of long term cardiovascular outcomes and new-onset diabetes with these same drugs. We also seek to define the mechanistic underpinnings of the genetic associations

PI: Dr. Julie A. Johnson

Role: Co-Investigator

RO1 GM099871-01A1 09/01/2012-05/31/2016 \$1,264,313.00

NIH/NIGMS-General Medical Science

Title: Developmental Pharmacology of cystolic and mitochondrial GSTZ1/MAAI

The broad, long-term objectives of this research are to understand the properties of glutathione transferase Z1 (GSTZ1) and its role in the elimination of haloacetic acids, particularly dichloroacetic acid (DCA) across

the human lifespan. This is important because while DCA has therapeutic benefits in treating certain solid tumors and in treating lactic acidosis, it exhibits marked individual variability in pharmacokinetics, and can cause side effects at high doses, particularly in adults.

PI: Dr. Margaret James

Role: Principal Investigator

Research Contract

UF-Micromedic Technologies, Nov.2014-Aug.2015 \$38,500

Title: Pharmacogenomics study of Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ)

PI: Dr. Taimour Langae

Role: Principal Investigator

UF Translational Science Institute (CTSI) Competitive Grant (2009) \$97,842

Title: Clinical, Genetic, and Microbial Interactions in Inflammatory Bowel Disease

PIs: Dr. Taimour Langae, Dr. Volker Mai, Dr. John Valentine

Role: Principal Investigator

UF Translational Science Institute (CTSI) Competitive Grant (2009) \$77,876

Title: Effects of OA-Related Pain on Telomere Length and Telomerase Activity

PIs: Dr. Roger Fillingim; Dr. Taimour Langae; Dr. Christiaan Leeuwenburgh

Role: Co-Principal Investigator

Research Grant 09/08/2008 - 09/07/2010 \$70,000

Micromedic Technologies (R-283)

Title: **Pharmacogenomics study of Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ)**

PIs: Dr. Joseph Katz; Dr. Taimour Langae

Role: Co-Investigator

U01 HL083459 08/2005-09/30/2010 \$11,149,034

Title: Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR-1)

PI: Dr. Julie Johnson

Role: Co-Investigator

R01 NS073346-01 03/15/2011 – 02/28/2015, \$2,065,191

Title: Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy (SPS3)

PI: Dr. Julie Johnson

Role: Co-Investigator

RO1-HL0747000; NIH/HLBI; 10/01/2003-09/30/2008 \$3,517,699.

Title: Hypertension Pharmacogenomics

PI: Dr. Julie Johnson);

Role: Co-Investigator

R01AG033906-07S1 09/30/2010-08/31/2011 \$1,172,306

NIH/NIA

Title: Ethnic Differences in Pain Responses-OppNet Competitive Revision

The overall aim of this competitive revision is determine the influence of chronic pain and psychosocial stress on TL and TA among older African American (AA) and non- Hispanic white (NHW) individuals with knee osteoarthritis (OA) as well as age and ethnicity-matched healthy controls.

PI: Dr. Roger Fillingim

Role: Co-Investigator

R01 ES 014617: NATL 04/18/2006 - 03/31/2011 \$2,401,263

NIH,

Title: Health Effects of Chlorinated Compounds: Pharmacotoxicology of Trichloroethylene Metabolites

The aims of this study are to quantify the influence of DCA, at exposure level ranging from environmental to clinical on human liver MAAI and tyrosine catabolism, establish the relationship between human MAAI

haplotype and DCA and tyrosine metabolism, and determine the in vivo kinetics and biotransformation of CH in healthy adults and influence of CH and DCA on each other's metabolism.

PI: Dr. Peter Stacpoole

Role: Co-Principal Investigator

UF Research and Graduate opportunity Fund Grant (2003) \$60,000

PI: Dr. Julie Johnson

Role: Co-Principal Investigator

UF Research and Graduate opportunity Fund Grant (2005) \$92,500

PI: Dr. Julie Johnson

Role: Co-Investigator

B 0435278 B AHA FL/Peurto Rico Affiliate 07/2004 to 06/2007 \$80,000

American Heart Association National Research Program

Title: Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

PI: Dr. Issam Zineh

Role: Co-Investigator

NIH/RO1 04/01/2005-03/30/2010, \$1,317,641

NIH (National Institute for Environmental Health Science, NIEHS);

Title; Health Effects of Chlorinated Compounds: Pharmacotoxicology of Trichloroethylene Metabolites

PI: Dr. Peter Stacpoole

Role: Co-Investigator

R21/R33 NIH Planning Grant 10/01/2007 to 12/31/2010

Aim: To plan and establish the feasibility of the key technology underlying a planned P50 proposal to support the expanding chemosensory clinical research program of the University of Florida's Center for Smell and Taste.

PI: Dr. Frank Catalanotto

Role: Co-Investigator

1U01GM092675-01 10/01/2009 to 09/30/2011 \$1,623,564

NIH, National Institute of General Medical Sciences,

Title: Role of Genetic Polymorphisms in Fructose and urate metabolism involved in Hypertension and the Metabolic syndrome

PI: Richard Johnson

Role: Co-Investigator

Source: NIDCR/NIAMS, 1RC1DE020520, 09/30/2009 to 09/29/2011 \$999,783

Title: Recurrent Aphthous Stomatitis: Planning Grant for a Genome-Wide Association Study

PI: Dr. Lorena Baccaglini

Patents

Patent application number: 20130035314

Inventors: Joseph Katz and Taimour Langaee, Yan Gong, Jan Moreb

METHODS AND KITS FOR DETECTING RISK FACTORS FOR DEVELOPMENT OF JAW OSTEONECROSIS AND METHODS OF TREATMENT THEREOF

United States Patent Application 20130090382

Inventors: Taimour Langaee and Peter Stacpoole

METHODS, ASSAYS, AND KITS RELATED TO DICHLOROACETATE (DCA)

PUBLICATIONS:

Book Chapter:

Langaee TY, and Hamadeh I.(Book chapter) **Applied Molecular and Cellular biology In: Pharmacogenomics: Applications to Patient Care (Third Edition)**. American College of Clinical Pharmacy (ACCP),2015.

Langaee TY, and Shin J.(Book chapter) **Concepts in Pharmacogenomics: The Genetic Basis of Pharmacogenomics**; In press by American Society of Health-System Pharmacists(ASHP), 2010.

Langaee TY, and Zineh I.(Book chapter) **Applied Molecular and Cellular biology In: Pharmacogenomics: Applications to Patient Care (Second Edition)**. American College of Clinical Pharmacy (ACCP), 2009.

Langaee TY, and Zineh I. (Book chapter) **Applied Molecular and Cellular biology In: Pharmacogenomics: Applications to Patient Care (First Edition)**. Published by American College of Clinical Pharmacy (ACCP), August 2004.

Reviewed book chapter:

"Pharmacogenomics and Laboratory Tests", **Basic Skills in Interpreting Laboratory Data**, edited by Mary Lee, 2008.

"Pharmacogenomics and Laboratory Tests", **Basic Skills in Interpreting Laboratory Data**, edited by Mary Lee, 2016.

Refereed Original Articles:

119. Taimour Langaee, Lynda Stauffer, Cheryl Galloway, Mohamed H. Solayman and Larisa Cavallari. Cross-Validation of High-Resolution Melting Analysis-Based genotyping platform. *Genetic Testing and Molecular Biomarkers*, Vol.21-4, 2017. DOI:10.1089/gtmb.20160317.

118. Hamadeh IS, Klinker KP, Borgert SJ, Richards AI, Li W, Mangal N, Hiemenz JW, Schmidt S, **Langaee TY**, Peloquin CA, Johnson JA, Cavallari LH. Impact of the *CYP2C19* genotype on voriconazole exposure in adults with invasive fungal infections. *Pharmacogenet Genomics* 2017 [Epub ahead of print]. PMID: 28306618.

117. Gong Y, Wang Z, Beitelshes AL, McDonough CW, **Langaee TY**, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic Genome-wide Meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. *Hypertension*. 2016;67:00-00. DOI: 10.1161/HYPERTENSIONAHA.115.06345.

116. Mohamed H. Shahin, Ana C. Sá, Amy Webb, Yan Gong, **Taimour Langaee**, Caitrin W. McDonough, Alberto Riva, Amber L Beitelshes, Arlene B. Chapman, John G., Stephen T. Turner, Eric Boerwinkle, Steven E. Scherer, Wolfgang Sadee, Rhonda M. Cooper-DeHoff¹, Julie A. Johnson. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. *Circ Cardiovasc Genet*. 2017 Jan;10(1). pii: e001404. doi: 10.1161/CIRCGENETICS.116.001404.

115. Larisa H. Cavallari, Oyunbileg Magvanjav, R. David Anderson, Rhonda M. Cooper-Dehoff, PharmD, Yan Gong, Aniwaa Owusu-Obeng, Ben Kong, Teresa Vo, Jennifer N. Ashton, Benjamin J. Staley, Amanda R. Elsey, MHA, R. W. Allen, Petr Starostik, **Taimour Y. Langaee**, Kristin W. Weitzel, Michael J. Clare-Salzler, David R. Nelson, Julie A. Johnson. Impact of Clinical Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy on Major Adverse Cardiovascular Outcomes. Submitted, 2017.

114. LM.Shaddox, A. Mullersman, H. Huang, S. Wallet, **T. Langaee**, and I. Aukhil. Epigenetic Regulation of Inflammation in Localized Aggressive Periodontitis. Submitted 2017.

113. Deanna Colli, Hao Tan, Jin Shouguang, **Taimour Langaee**, Thomas Bannister, Justin Shumate, Louis Scampavia, Timothy P. Spicer. A Rapid Phenotypic Whole Cell Screening Approach for the Identification of Small Molecule Inhibitors that Counter Beta-lactamase Resistance in *Pseudomonas aeruginosa*. Submitted 2017.

112. Yan Gong, Issam Hamadeh, Anita Szady, Hoai Khanh Nguyen, Qian Sun, Chintan Shah, **Taimour Langaee**, Rhonda M. Cooper-DeHoff, Gloria Lipori, Carl J. Pepine, Alexandra R. Lucas, Jan S. Moreb. Assessing the Incidence of Cardiomyopathy Associated with Targeted Cancer Therapies in a Real World Setting using Electronic Health Records. Submitted 2017.

111. Farhangi H, Ghasemi A, Banihashem A, Badiei Z, Jarahi L, Eslami G, **Langaee T**. Clinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old. Iran J Ped Hematol Oncol. 2016;6(1):24-31. PMID:27222699

110. Chang SW, Gong Y, McDonough CW, **Langaee TY**, Nasiri Kenari N, Beitelshes AL, Gums JG, Chapman AB, Turner ST, Johnson JA, Cooper-DeHoff RM. Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation? Clin Transl Sci. 2016 Mar 7. doi: 10.1111/cts.12389. [Epub ahead of print]

109. Issam S. Hamadeh, Mohamed H. Shahin, Sarah M. Lima, Felipe Oliveira, Latrice Wilson, Sherief I. Khalifa, **Taimour Y. Langaee**, Rhonda Cooper-DeHoff, Larisa H. Cavallari, Julie A. Johnson. Impact of *GGCX*, *STX1B* and *FPGS* Polymorphisms on Warfarin Dose Requirements in European Americans and Egyptians. Clin Transl Sci. 2016 Jan 11. doi: 10.1111/cts.12385. [Epub ahead of print]

108. L. Forest Gruss, **Taimour Langaee**, Andreas Keil. The role of the COMT val158met polymorphism in mediating aversive learning in visual cortex. Neuroimage. 2015 Nov 5;125:633-642. doi: 10.1016/j.neuroimage.2015.11.003. [Epub ahead of print].

107. Mohamed Solayman, **Taimour Langaee**, Archanakumari Patel, Lamia El-Wakeel, Manal El-Hamamsy, Osama Badary, Julie A. Johnson. Identification of Suitable Endogenous Normalizers for Quantitative Real-Time PCR Analysis of Circulating microRNA Expression in Essential Hypertension. Mol Biotechnol. 2016 Jan 21. [Epub ahead of print]

106. Hao-Jie Zhu, **Taimour Langaee**, Yan Gong, Xinwen Wang, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Julie A. Johnson, John S. Markowitz. No association between the *CES1P1* variant -816A>C with hepatic carboxylesterase 1 expression and activity and antihypertensive effect of trandolapril. *Eur J Clin Pharmacol* Eur J Clin Pharmacol. 2016 Feb 26. [Epub ahead of print]

105. Basma M. Khalil, Mohamed Hossam A. Shahin, Mohamed Hassan M. Solayman, **Taimour Langaee**, Mona F. Schaalán, Yan Gong, Lamiaa N. Hammad, Hala O. Al-Mesallamy, Nadia M. Hamdy, Walid A. El-Hammady, and Julie A. Johnson. Genetic and Non-Genetic Factors Affecting Clopidogrel Efficacy in Egyptian Population. Clin Transl Sci. 2016 Jan 12. doi: 10.1111/cts.12383. [Epub ahead of print]

104. Stephan C Jahn, Mohamed H Solayman, Ryan J Lorenzo, **Taimour Langaee**, Peter W Stacpoole, Margaret James. Intratumoral factors modulate sensitivity of cancer cells to dichloroacetate. Biochim Biophys Acta. 2016 Feb 2. pii: S0304-4165(16)30010-1. doi: 10.1016/j.bbagen.2016.01.024. [Epub ahead of print]

103. **Taimour Langaee**, Guo Zhong, Wenjun Li, Issam Hamadeh, Mohamed Hassan M. Solayman, Caitrin W. McDonough, Peter W. Stacpoole and Margaret O. James. The influence of human *GSTZ1* gene haplotype variations on *GSTZ1* expression. Pharmacogenet Genomics. 2015 Mar 3. [Epub ahead of print] PMID:25738370

102. **Langaee T**, Hamadeh I, Chapman AB, Gums JG, Johnson JA. A novel simple method for determining *CYP2D6* gene copy number and identifying allele(s) with duplication/multiplication. PLoS One. 2015 Jan 27;10(1):e0113808. doi: 10.1371

101. Johnson JA, Hamadeh IS, **Langaee TY**. Loss of Heterozygosity at the *CYP2D6* Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies. J Natl Cancer Inst. 2015 Jan 31; 107(2). pii: dju437.

100. **Taimour Langaee**, Hao-Jie Zhu, Xinwen Wang, Nihal El Rouby, John S. Markowitz, Joyce A. Goldstein, and Julie A. Johnson. The influence of the *CYP2C19*10* allele on clopidogrel activation and *CYP2C19*2* genotyping. Pharmacogenet Genomics. 2014 Aug; 24(8):381-6. doi: 10.1097.

- 99.** Fereidoun Forghani, **Taimour Langaee**, Mohammad Eskandari, Kun-Ho Seo, Mi-Ja Chung, Deog-Hwan Oh. Rapid Detection of Viable *Bacillus cereus* Emetic and Enterotoxic Strains in Food by Coupling Propidium Monoazide and Multiplex PCR (PMA-mPCR). In Press *Food Control*, 2015. doi:10.1016/j.foodcont.2015.02.049
- 98.** Brian L. Hoh, Yan Gong, Michael F. Waters, Adrienne J. Royster, Tiffany O. Sheehan, Ben Burkley, **Taimour Y. Langaee**, Caitrin W. McDonough, J Mocco, Scott L. Zuckerman, Nishit Mummareddy, Marcus L. Stephens II, Christie Ingram, Christian M. Shaffer, Joshua C. Denny, Murray H. Brilliant, Terrie E. Kitchner, James G. Linneman, Dan M. Roden, Julie A. Johnson. CYP2C19 and CES1 Polymorphisms and Efficacy of Clopidogrel and Aspirin Dual Antiplatelet Therapy in Patients with Symptomatic Intracranial Atherosclerotic Disease. *J Neurosurg*. 2015 Nov 20:1-6. [Epub ahead of print].
- 97.** Gong Y, McDonough CW, Beitelshes AL, Rouby NE, Hiltunen TP, O'Connell JR, Padmanabhan S, **Langaee TY**, Hall K, Schmidt SO, Curry RW Jr, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. *J Hypertens*. 2015 Nov;33(11):2278-2285.
- 96.** Mohamed Solayman, **Taimour Y. Langaee**, Yan Gong, Stephen T. Turner, Arlene B. Chapman, John G. Gums, Eric Boerwinkle, Amber L. Beitelshes, Manal El-Hamamsy, Lamia El-Wakeel, Rhonda M. Cooper-DeHoff, Osama Badary, Julie A. Johnson. Effect of Plasma MicroRNA on Antihypertensive Response to Beta Blockers in European Americans in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Submitted, 2015.
- 95.** Michelle M. Hwang, Hyun-Ji Choi, **Taimour Y. Langaee**, Henrietta L. Logan and Kevin P. Raisch. Analysis of saliva samples from healthy adults in north central Florida for human papillomavirus infection. Submitted 2015.
- 94.** Vonetta M Dotson, Fang-Chi Hsu, **Taimour Langaee**, Caitrin McDonough, Abby King, Ronald Cohen, Anne Newman, Stephen Kritchevsky, Valerie Myers, Todd Manini, Marco Pahor; For the LIFE Study Group. Genetic Moderators of the Impact of Physical Activity on Depressive Symptoms. *J Frailty Aging*. 2016;5(1):6-14. doi: 10.14283/jfa.2016.76.
- 93.** Shroads AL, Coats BS, **Langaee T**, Shuster JJ, Stacpoole PW. Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans. *Drug Metabol Personal Ther*. 2015 Mar;30(1):49-55. doi: 10.1515/dmd.
- 92.** Shitalben R. Patel, **Taimour Y. Langaee**, Shan S. Wong, Larisa H. Cavallari. Pyrosequencing of the *CYP2C9* -1766T>C polymorphism as a means of detecting the *CYP2C9**8 allele. *Pharmacogenomics*. 2014 Sep;15(13):1717-22. doi: 10.2217/pgs.14.130.
- 91.** Efstratios K Theofilogiannakos, Konstantinos Dean Boudoulas, Brian E Gawronski, **Taimour Y Langaee**, Petros S Dardas, Vlasis Ninios, Timotheos G Kelpis, Julie A Johnson, Antonios A Pitsis, Harisios Boudoulas*. Floppy Mitral Valve/Mitral Valve Prolapse Syndrome: Beta-Adrenergic Receptor Polymorphism May Contribute to the Pathogenesis of Symptoms. Accepted for publication in *Journal of Cardiology*, *J Cardiol*. 2014 Aug 26. pii: S0914-5087(14)00225-1. doi: 10.1016/j.jcc.2014.07.020. [Epub ahead of print].
- 90.** Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA, Klein TE, Limdi N, Hillenmeyer S, Percha B, Karczewski KJ, **Langaee T**, Patel SR, Bustamante CD, Altman RB, Perera MA. Genetic variant in folate homeostasis associated with lower warfarin dose in African Americans. *Blood*. 2014 Jul 30. pii: blood-2014-04-568436. [Epub ahead of print]
- 89.** Shroads AL, Coats BS, McDonough CW, **Langaee T**, Stacpoole PW. Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children. *J Clin Pharmacol*. 2014 Jul 30. doi: 10.1002/jcph.371. [Epub ahead of print]

88. Hao-Jie Zhu, **Taimour Y. Langaee**, Yan Gong, Xinwen Wang, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Julie A. Johnson, John S. Markowitz. No association between the *CES1P1* variant -816A>C with hepatic carboxylesterase 1 expression and activity and antihypertensive effect of trandolapril. *Submitted, 2015.*

87. Yolande B. Saab, **Taimour Langaee**, and Rony Zeenny. EFFECT OF THE GLOBAL VARIATION OF THE GENETIC BIOMARKER URIDINE DIPHOSPHATE GLUCURONOSYL TRANSFERASE. 2014, International Journal of Pharmacy and Pharmaceutical Sciences.

86. Issam S. Hamadeh, **Taimour Y. Langaee**, Ruti Dwivedi, Sofia Garcia, Ben M. Burkley, Arlene B. Chapman, John G. Gums, Stephen T. Turner, Yan Gong, Rhonda M. Cooper-Dehoff, and Julie A. Johnson. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of immediate release metoprolol tartrate. *Clin Pharmacol Ther.* 2014 Mar 17. doi: 10.1038/clpt.2014.62. [Epub ahead of print]

85. Zhong G, Li W, Gu Y, **Langaee T**, Stacpoole PW, James MO. Chloride and other anions inhibit dichloroacetate-induced inactivation of human liver GSTZ1 in a haplotype-dependent manner. *Chem Biol Interact.* 2014 Mar 12. pii: S0009-2797(14)00076-3. doi: 10.1016/j.cbi.2014.02.015. [Epub ahead of print]

84. Kristin W. Weitzel, Amanda R. Elsey, **Taimour Y. Langaee**, Benjamin Burkley, David R. Nessler, Aniwa Obeng, Ben Staley, Hui-Jia Dong, Robert W. Allan, J. Felix Liu, Rhonda M. Cooper-DeHoff, R. David Anderson, Michael Conlon, Michael J. Clare-Salzler, David R. Nelson, Julie A. Johnson. Clinical Pharmacogenetics Implementation: Approaches, Successes, and Challenges. *Am J Med Genet C Semin Med Genet.* 2014 Mar 10. doi: 10.1002/ajmg.c.31390. [Epub ahead of print] PMID:24616371.

83. Vandell AG, McDonough CW, Gong Y, **Langaee TY**, Lucas AM, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Hydrochlorothiazide-Induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *J Intern Med.* 2014 Feb 12. doi: 10.1111/joim.12215. [Epub ahead of print] PMID:24612202.

82. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshes A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, Cooper-Dehoff RM, Gaunt TR, Gieger C, Gong Y, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP, O'Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Verschuren WM, Anand SS, Dominiczak A, Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T, Johnson JA, Kirkland S; the Look AHEAD Research Group, König W, **Langaee TY**, McCaffery J, Melander O, Mitchell BD, Munroe P, Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, van der Schouw YT, Shimbo D, Shuldiner AR, Tobin MD, Wijmenga C, Yusuf S; the GIANT Consortium; the CARE IBC Consortium, Hakonarson H, Lange LA, Demerath EW, Fox CS, North KE, Reiner AP, Keating B, Taylor KC. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet.* 2013 Dec 17. [Epub ahead of print]

Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med.* 2013 Dec 12;369(24):2283-93, 2013 Nov 19.

81. Dunbar EM, Coats BS, Shroads AL, **Langaee T**, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. *Invest New Drugs.* 2013 Dec 3. [Epub ahead of print]

80. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MHA, Buford TW, El Roubi NM, Sá ACC, Langaee TY, Gums JG, Chapman AB, Cooper-DeHoff RM, Turner ST, Gong Y, Johnson JA. Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *PLoS One.* 2013; 8(10):e76984.

79. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, **Langaee TY**, Pepine CJ, Johnson JA, Cooper-Dehoff RM. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. *Pharmacogenet Genomics.* 2013 Dec;23(12):697-705.

78. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, **Langaee** TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet*. 2013 Aug 31;382(9894):790-6.

77. Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Del-Aguila JL, Boerwinkle EA, Pepine CJ, Turner ST, Johnson JA, Cooper-DeHoff RM. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. *Pharmacogenomics J*. 2013; 13(5):430-436.

76. McDonough CW, Gong Y, Padmanabhan S, Burkley B, **Langaee** TY, Melander O, Pepine CJ, Dominiczak AF, Cooper-Dehoff RM, Johnson JA. Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes. *Hypertension*. 2013 May 20. [Epub ahead of print] PMID:23690342

75. Abdelmalak M, Lew A, Ramezani R, Shroads AL, Coats BS, **Langaee** T, Shankar MN, Neiberger RE, Subramony SH, Stacpoole PW. Long-term safety of dichloroacetate in congenital lactic acidosis. *Mol Genet Metab*. 2013 Apr.

74. Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, **Langaee** T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. *Thromb Haemost*. 2013 Mar 21;109(6). [Epub ahead of print]

73. McDonough CW, Burbage SE, Duarte JD, Gong Y, **Langaee** TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshes AL, Boerwinkle E, Pepine CJ, Cooper-Dehoff RM, Johnson JA. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens*. 2013 Jan 30. [Epub ahead of print] PMID:23353631

72. Karnes JH, **Langaee** TY, McDonough CW, Chang SW, Ramos M, Catlin JR Jr, Casanova OE, Gong Y, Pepine CJ, Johnson JA, Cooper-Dehoff RM. Lack of association of the HMGGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. *J Transl Med*. 2013 Jan 9;11(1):12. [Epub ahead of print] PMID:23302499

71. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JM, Gieger C, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Most PJ, Van Iperen EP, van Setten J, Vonk JM, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Boer JM, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, Cooper-Dehoff RM, Curtis SP, Dreisbach A, Duggan D, Ehret GB, Fabsitz RR, Fornage M, Fox E, Furlong CE, Gansevoort RT, Hofker MH, Hovingh GK, Kirkland SA, Kottke-Marchant K, Kutlar A, Lacroix AZ, **Langaee** TY, Li YR, Lin H, Liu K, Maiwald S, Malik R; METASTROKE, Murugesan G, Newton-Cheh C, O'Connell JR, Onland-Moret NC, Ouweland WH, Palmas W, Penninx BW, Pepine CJ, Pettinger M, Polak JF, Ramachandran VS, Ranchalis J, Redline S, Ridker PM, Rose LM, Scharnag H, Schork NJ, Shimbo D, Shuldiner AR, Srinivasan SR, Stolk RP, Taylor HA, Thorand B, Trip MD, van Duijn CM, Verschuren WM, Wijmenga C, Winkelmann BR, Wyatt S, Young JH, Boehm BO, Caulfield MJ, Chasman DI, Davidson KW, Doevendans PA, Fitzgerald GA, Gums JG, Hakonarson H, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJ, Koenig W; LifeLines Cohort Study, März W, Mitchell BD, Murray SS, Oldehinkel AJ, Rader DJ, Reilly MP, Reiner AP, Schadt EE, Silverstein RL, Snieder H, Stanton AV, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Johnson AD, Munroe PB, de Bakker PI, Zhu X, Levy D, Keating BJ, Asselbergs FW. Loci influencing blood pressure identified using a cardiovascular gene-centric array. *Hum Mol Genet*. 2013 Jan 8. [Epub ahead of print] PMID:23303523 [PubMed - as supplied by publisher]

70. Beitelshes A, Aquilante C, Allayee H, **Langaee** T, Welder G, Schofield R, Zineh I. CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults. *Hum Genomics*. 2012 Aug 2;6(1):9. [Epub ahead of print]

69. Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, **Langaee T**, Siguret V, Lorient MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C. Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. *Clin Pharmacol Ther.* 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Epub 2012 Nov 7.

68. Gong Y, McDonough CW, Wang Z, Hou W, Cooper-Dehoff RM, **Langaee TY**, Beitelshes AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives - Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Circ Cardiovasc Genet.* 2012 Oct 19. [Epub ahead of print] PMID:23087401

67. Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera B, Appelman YE, Barnard J, Baumert J, Beitelshes AL, Bhangale TR, Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, **Langaee TY**, Li M, Li YR, Liu K, McDonough CW, Meijis MF, Middelberg RP, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SP, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JM, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, Cooper-Dehoff RM, Cupples LA, Dejong JS, Delles C, Duggan D, Fornage M, Furlong CE, Glazer N, Gums JG, Hastie C, Holmes MV, Illig T, Kirkland SA, Kivimaki M, Klein R, Klein BE, Kooperberg C, Kottke-Marchant K, Kumari M, Lacroix AZ, Mallela L, Murugesan G, Ordovas J, Ouwehand WH, Post WS, Saxena R, Scharnagl H, Schreiner PJ, Shah T, Shields DC, Shimbo D, Srinivasan SR, Stolk RP, Swerdlow DI, Taylor HA Jr, Topol EJ, Toskala E, van Pelt JL, van Setten J, Yusuf S, Whittaker JC, Zwinderman AH; LifeLines Cohort Study, Anand SS, Balmforth AJ, Berenson GS, Bezzina CR, Boehm BO, Boerwinkle E, Casas JP, Caulfield MJ, Clarke R, Connell JM, Cruickshanks KJ, Davidson KW, Day IN, de Bakker PI, Doevendans PA, Dominiczak AF, Hall AS, Hartman CA, Hengstenberg C, Hillege HL, Hofker MH, Humphries SE, Jarvik GP, Johnson JA, Kaess BM, Kathiresan S, Koenig W, Lawlor DA, März W, Melander O, Mitchell BD, Montgomery GW, Munroe PB, Murray SS, Newhouse SJ, Onland-Moret NC, Poulter N, Psaty B, Redline S, Rich SS, Rotter JI, Schunkert H, Sever P, Shuldiner AR, Silverstein RL, Stanton A, Thorand B, Trip MD, Tsai MY, van der Harst P, van der Schoot E, van der Schouw YT, Verschuren WM, Watkins H, Wilde AA, Wolfenbutter BH, Whitfield JB, Hovingh GK, Ballantyne CM, Wijmenga C, Reilly MP, Martin NG, Wilson JG, Rader DJ, Samani NJ, Reiner AP, Hegele RA, Kastelein JJ, Hingorani AD, Talmud PJ, Hakonarson H, Elbers CC, Keating BJ, Drenos F. Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. *Am J Hum Genet.* 2012 Oct 10. pii: S0002-9297(12)00474-0. doi: 10.1016/j.ajhg.2012.08.032. [Epub ahead of print] PMID:23063622

66. Vandell AG, Lobmeyer MT, Gawronski BE, **Langaee TY**, Gong Y, Gums JG, Beitelshes AL, Turner ST, Chapman AB, Cooper-Dehoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 (GRK4) polymorphisms: Beta-blocker pharmacogenetics and treatment related outcomes in hypertension. *Hypertension* 2012 Oct;60(4):957-64.

65. Johnson JA, Burkley BM, **Langaee TY**, Clare-Salzler MJ, Klein TE, Altman RB. Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array. *Clin Pharmacol Ther.* 2012 Aug 22. doi: 10.1038/clpt.2012.125. [Epub ahead of print]

64. Shafiu M, Johnson RJ, Turner ST, **Langaee T**, Gong Y, Chapman AB, Gums JG, Johnson JA. Urate Transporter Gene SLC22A12 Polymorphisms Associated with Obesity and Metabolic Syndrome in Caucasians with Hypertension. *Kidney Blood Press Res.* 2012 Jun 8;35(6):477-482. [Epub ahead of print] PMID: 22688828

63. Duarte JD, Zineh I, Burkley B, Gong Y, **Langaee TY**, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-Dehoff RM, Beitelshes AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. *J Transl Med.* 2012 Mar 22;10:56.

62. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, **Langaee TY**, Beitelshes AL, Cooper-Dehoff RM, Boerwinkle E, Johnson JA. Association of chromosome 12 locus with antihypertensive

response to hydrochlorothiazide may involve differential YEATS4 expression. *Pharmacogenomics J.* 2012 Feb 21. doi: 10.1038/tpj.2012.4. [Epub ahead of print]

61. Sibille KT, **Langaee T**, Burkley B, Gong Y, Glover TL, King C, Riley JL 3rd, Leeuwenburgh C, Staud R, Bradley LA, Fillingim RB. Chronic pain, perceived stress, and cellular aging: an exploratory study. *Mol Pain.* 2012 Feb 12;8(1):12. [Epub ahead of print]

60. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-Dehoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, Gong Y, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, **Langaee TY**, Lawlor DA, Li M, Lobmeyer MT, Maitland-van der Zee AH, Meijs MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolfenbutter BH, Young T, Zafarmand MH, Zmuda JM; the Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Caulfield M, Dominiczak A, Shields DC, Bhatt D, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW 2nd, Farrall M, Fitzgerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs F, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ. **Large-Scale Gene-Centric Meta-Analysis across 39 studies Identifies Type 2 Diabetes Loci.** *Am J Hum Genet.* 2012 Feb 8. [Epub ahead of print]

59. Wang D, Sun X, Gong Y, Gawronski BE, **Langaee TY**, Shahin MH, Khalifa SI, Johnson JA. CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism (pVNTR) Regulates mRNA Expression in Human Livers. *Drug Metab Dispos.* 2012 Jan 30. [Epub ahead of print]

58. Wenjun Li, Yuan Gu, Margaret O. James, Ronald N. Hines, Pippa Simpson, **Taimour Langaee** and Peter W. Stacpoole. Prenatal and postnatal expression of glutathione transferase zeta 1 in human liver and the role of haplotype and subject age in determining activity with dichloroacetate. *Drug Metab Dispos.* 2011 Oct 25.

57. Shin J, Pauly DF, Pacanowski MA, **Langaee T**, Frye RF, Johnson JA. Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin. *Pharmacotherapy.* 2011 Oct;31(10):942-50

56. Gong Y, Beitelshes AL, Cooper-DeHoff RM, Lobmeyer MT, **Langaee TY**, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Response to Letter Regarding Article "Chromosome 9p21 Haplotypes and Prognosis in white and Black Patients with Coronary Artery Disease". *Circ Cardiovasc Genet.* 2011;4 (4): e12. PMID: 21846865

55. Larisa H. Cavallari, Christopher Butler, **Taimour Y. Langaee**, Nargis Wardak, Shitalben R. Patel, Marlos A.G. Viana, Nancy L. Shapiro, Edith A. Nutescu. Apolipoprotein E Genotype Association with Time to Stable Warfarin Dosing in African Americans. *Pharmacotherapy* 2011;31(8):785–792.

54. Shroads AL, **Langaee T**, Coats BS, Kurtz TL, Bullock JR, Weithorn D, Gong Y, Wagner DA, Ostrov DA, Johnson JA, Stacpoole PW. Human Polymorphisms in the Glutathione Transferase Zeta 1/Maleylacetoacetate Isomerase Gene Influence the Toxicokinetics of Dichloroacetate. *J Clin Pharmacol.* 2011 Jun 3. [Epub ahead of print]

53. Katz J, Gong Y, Samasinia D, Hour W, Burkley B, Ferriera P, Casanova O, **Langaee T**, Moreb J. Genetic Polymorphisms and other risk factors Associated with Bisphosphonate induced Osteonecrosis of the Jaw (BONJ) *Int J Oral Maxillofac Surg.* 2011 Mar 10. [Epub ahead of print]

52. Gong Y, Beitelshes AL, Cooper-Dehoff RM, Lobmeyer MT, **Langaee TY**, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 Haplotypes and Prognosis in Caucasian and African American Patients with Coronary Artery Disease. *Circ Cardiovasc Genet*. 2011 Mar 3. [Epub ahead of print]
51. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, Ali SS, Mohamed ME, **Langaee T**, Johnson JA. Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. *Pharmacogenet Genomics*. 2011 Jan 11. [Epub ahead of print]
50. Niu Y, Gong Y, **Langaee TY**, Davis H, Elewa H, Beitelshes AL, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Genetic Variation in the Beta 2 Subunit of the Voltage-Gated Calcium Channel (*CACNB2*) and Pharmacogenetic Association with Adverse Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study-Genetic Substudy (INVEST-GENES) *Circ Cardiovasc Genet*, 2010;3:548-555 PMID: 21156931.
49. Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, **Langaee T**. ampG gene of *Pseudomonas aeruginosa* and its role in β -lactamase expression. *Antimicrob Agents Chemother*. 2010 Nov;54(11):4772-9. Epub 2010 Aug 16.
48. Jaekyu Shin, Daniel F. Pauly, Michael A. Pacanowski, **Taimour Langaee**, Reginald F. Frye, and Julie A. Johnson. Effect of *CYP3A5* genotype on atorvastatin pharmacokinetics and interaction with clarithromycin. (In Press, *Pharmacotherapy*, 2011).
47. Mohamed Shafiu, Richard J. Johnson, Stephen T. Turner, **Taimour Langaee**, Yan Gong, Arlene B. Chapman, John G. Gums, Julie Johnson. Uric acid transporter gene SLC22A12 polymorphisms associated with obesity, low HDL and metabolic syndrome in Caucasians with Primary Hypertension. (Submitted, 2010).
46. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. *Blood*. 2010 May 6;115(18):3827-34. Epub 2010 Mar 4.
45. Larisa H. Cavallari, **Taimour Y. Langaee**, Kathryn M. Momary, Nancy L. Shapiro, Edith A. Nutescu, Marlos A.G. Viana, Shital R. Patel, Julie A. Johnson. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. *Clin Pharmacol Ther*. 2010 Apr;87(4):459-64. Epub 2010 Jan 13.
44. Julio D. Duarte, Maximilian T. Lobmeyer, Zhiying Wang, Arlene B. Chapman, John G. Gums, **Taimour Y. Langaee**, Eric Boerwinkle, Stephen T. Turner, and Julie A. Johnson. Lack of association between polymorphisms in *STK39*, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. *Pharmacogenet Genomics*. 2010 Aug;20(8):516-9.
43. Amber L. Beitelshes, Hrishikesh Navare, Danxin Wang, Yan Gong, Jennifer Wessel, James Moss, **Taimour Y. Langaee**, Rhonda M. Cooper-DeHoff, Wolfgang Sadee, Carl J. Pepine, Nicolas J. Schork, Julie A. Johnson. *CACNA1C* gene polymorphisms, cardiovascular disease outcomes and treatment response. *Circ Cardiovasc Genet*. 2009;2:362-370.
42. Pinedo PJ, Buergelt CD, Donovan GA, Melendez P, Morel L, Wu R, **Langaee TY**, Rae DO. Candidate gene polymorphisms (BoIFNG, TLR4, SLC11A1) as risk factors for paratuberculosis infection in cattle. *Prev Vet Med*. 2009 Jun 12. [Epub ahead of print]
41. **International Warfarin Pharmacogenetics Consortium**, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med*. 2009 Feb 19;360(8):753-64.
40. Dungan JR, Conley YP, **Langaee TY**, Johnson JA, Kneipp SM, Hess PJ, Yucha CB. Altered Beta-2 Adrenergic Receptor Gene Expression in Human Clinical Hypertension. *Biol Res Nurs*. 2009 Mar 1. [Epub ahead of print]

39. Shin Jaekyu, Steven Kayser, **Taimour Langaee**. Pharmacogenetics: From Discovery to Patient Care. (In press in, Am J Health Syst Pharm., 2009).
38. Schentrup AM, Allayee H, Lima JJ, Johnson JA, **Langaee TY**. Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (*ALOX5*) by pyrosequencing assay. Genet Test Mol Biomarkers. 2009 Jun;13(3):361-5.
37. Yan Gong, Amber L. Beitelshes, **Taimour Y. Langaee**, Rhonda M. Cooper-DeHoff, Jun Wu, John A. Spertus, Michael A. Province, Carl J. Pepine, Julie A. Johnson. Chromosome 9p21 SNPs and Cardiovascular Outcomes in Hypertensive Patients with Coronary Artery Diseases. Submitted, 2009.
36. Hasani Ranjbar S, Amiri P, Zineh I, **Langaee TY**, Namakchian M, Heshmet R, Sajadi M, Mirzaee M, Rezazadeh E, Balaei P, Tavakkoly Bazzaz J, Gonzalez-Gay MA, Larijani B, Amoli MM. CXCL5 gene polymorphism association with diabetes mellitus. Mol Diagn Ther. 2008;12(6):391-4.
35. Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, **Taimour Y. Langaee**, Charles Eby, Cristi King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto J. Vidaillet, Steven H Yale, Kai Qi Zhang, Richard L. Berg, and James K Burmester. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 Apr 15;111(8):4106-12. Epub 2008 Feb 4.
34. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, **Langaee T**, Farnett LE, Voora D1, Veenstra DL, Glynn R, Barrett A, and McLeod HL. Use of Pharmacogenetics and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clin Pharmacol Ther. 2008 Feb 27; [Epub ahead of print]
33. Hassan M, York KM, Li H, Li Q, Gong Y, **Langaee TY**, Fillingim RB, Johnson JA, Sheps DS. β -Adrenergic Receptor Polymorphisms Predict Hemodynamic and Myocardial Ischemic Responses to Mental Stress in Patients with Coronary Artery Disease. Arch Intern Med. 2008 Apr 14;168(7):763-70.
32. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, **Langaee TY**, Markowitz JS. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008 Jun;82(6):1241-8. PMID: 18485328
31. Salha MD, Cheynier R, Halwani R, McGrath H, **Langaee TY**, Yassine Diab B, Fournier J, Parenteau M, Edgar J, Ko D, Sherring A, Bogdanovic D, Sekaly RP, Rud EW. Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection. Virology. 2008 Aug 1;377(2):239-47
30. Gregory M. Cooper, Julie A. Johnson, **Taimour Y. Langaee**, Hua Fang, Ian B. Stanaway, Marylyn D. Ritchie, Dan M. Roden, Joshua D. Smith, Dave L. Veenstra, Allan E. Rettie, Mark J. Rieder. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008 Jun 5. [Epub ahead of print]
29. G. Oner Ozgon, **T.Y. Langaee**, H. Feng, N. Buyru, T. Ulutin, A.C. Hatemi, A. Siva, S. Saip, J.A. Johnson. *VKORC1* and *CYP2C9* polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol. 2008 Jun 10. [Epub ahead of print]
28. Stacpoole PW, Kurtz TL, Han Z, **Langaee T**. Role of Dichloroacetate in the Treatment of Genetic Mitochondrial Diseases. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1478-87.
27. Gerhard T, Gong Y, Beitelshes AL, Lobmeyer M, Cooper-DeHoff RM, **Langaee TY**, Schork NJ, Pepine CJ, Johnson JA. Association between Cardiovascular Outcomes, Diuretics Therapy and the α -adducin Polymorphism: Results from the International Verapamil STudy GENetic substudy (INVEST-GENES), Am Heart J. 2008 Aug;156(2):397-404. Epub 2008 Jun 20.

26. M.A. Pacanowski, Y. Gong, R.M. Cooper-DeHoff, N.J. Schork, M.D. Shriver, **T.Y. Langaee**, C.J. Pepine, J.A. Johnson, for the INVEST investigators. β -adrenergic receptor gene polymorphisms and β -blocker treatment outcomes in hypertension Clin Pharmacol Ther. 2008 Jul 9. [Epub ahead of print]
25. Pablo J. Pinedo, Claus D. Buergelt, G. Art Donovan, J. Elliot Williams, Pedro Melendez, Laurence Morel, Rongling Wu, **Taimour Y. Langaee** and D. Owen Rae. Association between *CARD15/NOD2* gene polymorphisms and paratuberculosis infection in Florida cattle. Vet Microbiol. 2008 Sep 19. [Epub ahead of print].
24. Johnson AD, Gong Y, Wang D, **Langaee TY**, Shin J, Cooper-DeHoff RM, Schork NJ, Binkley P, Pepine CJ, Johnson JA, Sadee W. Promoter polymorphisms in *ACE* (angiotensin-I converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther. 2008 Oct 22. [Epub ahead of print].
23. Mohamed-Eslam F.Mohamed, Reginald F. Frye, and **Taimour Y. Langaee**. Inter-population variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms. Genet Test. 2008 Nov 2. [Epub ahead of print]
22. Mahsa Amoli, Parvin Amiri, Issam Zineh, **Taimour Y. Langaee**, Shirin Hasani Ranjbar *et al.* CXCL5 gene polymorphism association with diabetes. Mol Diagn Ther. 2008;12(6):391-4.
21. Zineh I, Aquilante CL, **Langaee TY**, Beitelshes AL, Arant CB, Wessel TR, Schofield RS. CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine 2006 Mar 7;33(5):258-63. Epub 2006 Mar 29.
20. Aquilante CL, **Langaee TY**, Anderson PL, Zineh I, Fletcher CV. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clin Chim Acta. 2006 Oct;372(1-2):195-8. Epub 2006 May 15.
19. Ortega M, **Langaee TY**, Gong Y, Feng H, Johnson JA. G protein β 3 subunit (GN β 3) Polymorphism and Hypertension. UF Journal of Undergraduate Research, Volume 7, Issue 4 - March/April 2006.
18. Aquilante CL, Zineh I, Beitelshes AL, **Langaee TY**. Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm. 2006 Nov 1;63(21):2101-2110.
17. Shin J, Lobmeyer MT, Gong Y, Zineh I, **Langaee TY**, Yarandi H, Schofield RS, Aranda JM Jr, Hill JA, Pauly DF, Johnson JA. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 2007 Jan 15;99(2):250-5.
16. **Langaee TY**, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007 Mar;81(3):386-91.
15. Gong Y, Beitelshes AL, Wessel J, **Langaee TY**, Schork NJ, Johnson JA. Single nucleotide polymorphism discovery and haplotype analysis of Ca²⁺-dependent K⁺ channel beta-1 subunit. Pharmacogenetics and Genomics 2007;17:267-275.
14. Lobmeyer MT, Gong Y, Terra SG, Beitelshes AL, **Langaee TY**, Pauly DF, Schofield RS, Hamilton KK, Patterson HJ, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenetics and Genomics 2007 17:277-282.
13. Brunner M, Cooper-Dehoff RM, Gong Y, Karnes JH, **Langaee TY**, Pepine CJ, Johnson JA; INVEST Investigators. Factors Influencing Blood Pressure Response to Trandolapril Add-on Therapy in Patients taking Verapamil SR (From the International Verapamil SR/Tandolapril [INVEST] Study). Am J Cardiol 2007 Jun 1;99(11):1549-1554.
12. Levin, GM, Bowles TM, Ehrel MJ, **Langaee TY**, Tan JY, Johnson JA, and Millard W. Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness. Mol Diagn Ther 2007;11(3):155-160.

11. Beitelshes AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, **Langaee TY**, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA; for the INVEST Investigators. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics 2007 Sep;17(9):719-729.
10. Aquilante CL, **Langaee TY**, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther; 2006; 79:291-302.
9. Zineh I, Welder GJ, **Langaee TY**. Development and cross-validation of sequencing-based assays for genotyping common polymorphisms of the CXCL5 gene. Clin Chim Acta. 2006 Aug;370(1-2):72-5. Epub 2006 Mar 29.
8. Hruska MW, Amico JA, **Langaee TY**, Ferrell RE, Fitzgerald SM, Frye RF. The Effect of Trimethoprim on CYP2C8 Mediated Rosiglitazone Metabolism in Human Liver Microsomes and Healthy Subjects. Br J Clin Pharmacol (2005);59(1):70-79.
7. **Langaee TY** and Ronaghi M. Genetic Variation Analyses by Pyrosequencing. Mutation Research (2005);573(1-2):96-102.
6. Ronaghi M, **Langaee TY**. Single Nucleotide Polymorphism: Discovery, Detection and Analysis. Personalized Medicine (2005);2(2):111-125.
5. Aquilante CL, Lobmeyer MT, **Langaee TY**, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004;24(6):720-6.
4. Johnson JA, **Langaee TY**, Zineh I and Beitelshes AL. Caution with β_1 -adrenergic receptor genotyping. Clinical Pharmacology & Therapeutics 2004;76(2):185-86.
3. Hruska MW, Frye RF, **Langaee TY**. Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 Enzymes. Clin Chem. 2004 Dec;50(12):2392-5.
2. **Langaee TY.**, Gagnon, L and Huletsky, A. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate basal level and hyperinducible AmpC beta-lactamase expression. Antimicrobial Agents and Chemotherapy Mar. 2000:583-589.
1. **Langaee TY.**, Dargis M and Huletsky A. An *ampD* gene in Pseudomonas aeruginosa encodes a negative regulator of AmpC beta-lactamase expression. Antimicrobial Agents and Chemotherapy Dec. 1998;3296-3300.

Membership

American Society of Human Genetics (ASHG)
American Society for the Advancement of Science (AAAS)
American Society for Microbiology (ASM)

AWARDS:

1996 ASM (American Society for Microbiology) Sustaining Member Student Grant.
1997 ASM (American Society for Microbiology) Sustaining Member Student Grant.

ABSTRACTS AND PRESENTATIONS:

I Zineh, PharmD, **TY Langaee, PhD**, JA Hill, MD, MS, DF Pauly, MD, PhD, RS Schofield, MD, JM Aranda, Jr., MD, and JA Johnson, PharmD. Type-A Natriuretic Peptide Receptor Polymorphism in Hypertension, Heart

Failure Prognosis, and Response to Nesiritide. Presented as a poster at the 2002 American College of Clinical Pharmacy Meeting, Cardiology Practice and research Network, Albuquerque, NM, October 2002.

A. Albekairy, Pharm.D., T. Luu, H. Yarandi, Ph.D., **T. Y. Langaee, Ph.D.**, C. Formea, Pharm.D., V. Greene, PA., S. Fujita, MD., W. Vander Werf, MD., A. Hemming, MD, R. Howard, MD., A. Reed, MD., J. Karlix, Pharm.D., University of Florida, College of Pharmacy and medicine, Gainesville, FL. CYTOCHROME P-450 3A4*1B AS PHARMACOGENOMIC PREDICTOR OF TACROLIMUS PHARMACOKINETICS AND CLINICAL OUTCOME IN THE LIVER TRANSPLANT RECIPIENTS. Presented as a poster at the 2002 American College of Clinical Pharmacy Meeting, Cardiology Practice and research Network, Albuquerque, NM, October 2002.

R.P. Rantinella, **T.Y. Langaee Ph.D.**, C. Aquilante PharmD., J.A. Johnson PharmD., University of Florida College of Pharmacy, Gainesville, FL. Association of Alpha 2b-Adrenergic Receptor Insertion/Deletion Polymorphism with Hypertension and Obesity. Selected for a poster presentation at the 104th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Marriott Wardman Park Hotel, Washington, DC. April 2-5, 2003.

Aquilante CL, Yarandi HN, **Langaee TY**, Tromberg JS, Lopez LM, Waddell CD, Johnson JA. University of Florida, College of Pharmacy and medicine, Gainesville, FL. The Influence of Coagulation Factor and CYP2C9 Polymorphisms on Warfarin Dose. Abstract was accepted by American Heart Association and will be presented at the American Heart Association meeting, Orlando, Florida, November 9-12, 2003.

TM Bowles, PharmD., GM Levin, PharmD., **TY Langaee, Ph.D.**, JY Tan, PharmD., HN Yarandi, Ph.D., JA Johnson, PharmD., WJ Millard, Ph.D. Assessment of serotonin type1A (5-HT1A) receptor genotype in a normal versus a depressed population and the relationship to predictability of antidepressant responsiveness. Abstract was accepted by American College of Clinical Pharmacy (ACCP) and will be presented at the 2003 American College of Clinical Pharmacy Meeting, Atlanta, GA, November 2-5, 2003.

Aquilante CL, Yarandi HN, **Langaee TY**, Tromberg JS, Lopez LM, Waddell CD, Johnson JA. The Influence of Coagulation Factor and CYP2C9 Polymorphisms on Warfarin Dose. University of Florida, College of Pharmacy and medicine, Gainesville, FL. Presented at the Annual Meeting of the American Heart Association (AHA) Meeting, Orlando, FL, November 2003.

T. Y. Langaee, Ph.D., R. C. Givens, BS, A. Sloan, MS., P. B. Watkins, MD., J. A. Johnson, PharmD. ASSOCIATION OF CYP3A5*3, *6, AND *7 POLYMORPHISMS WITH HYPERTENSION. University of Florida, Gainesville, FL, University of North Carolina, Chapel Hill, NC. Abstract was accepted by American Society for Clinical Pharmacology and Therapeutics (ASCPT) and presented at the 2004 American Society for Clinical Pharmacology and Therapeutics Meeting, Miami Beach, FL, March 25, 2004.

Gaston KL, Aquilante CL, **Langaee TY**, Lopez LM, Johnson JA. Vitamin K epoxide reductase polymorphisms rare in warfarin-treated population. Pharmacotherapy 2004; 24(10): 1458

J. R. Dungan, RN, MSN, ARNP, **T.Y. Langaee, MSPH, PhD**, J. A. Johnson, Pharm.D., and C. B. Yucha, PhD, RN. Exploring the Relationship Between Beta-2 Adrenergic Receptor Gene Polymorphisms and Biofeedback Outcomes in Hypertension. University of Florida, College of Pharmacy and medicine, Gainesville, FL. Abstract was accepted by Association for Applied Psychophysiology and Biofeedback (AABP) and will be presented at the 2004 Association for Applied Psychophysiology and Biofeedback Meeting, Colorado Springs, CO, April, 2004.

B.S. Belgado, L.H. Cavallari, **T. Langaee**, T. Okorochnikwu J. A. Johnson, PharmD. ASSOCIATION OF β 2-Adrenergic Receptor Haplotype and Hypertension in African-Americans and Caucasians. University of Florida, Gainesville, FL, University of Illinois at Chicago, College of Pharmacy. Abstract was accepted by American Society for Clinical Pharmacology and Therapeutics (ASCPT) and presented at the 2004 American Society for Clinical Pharmacology and Therapeutics Meeting, Miami Beach, FL, March 25, 2004.

C. Formea, PharmD., T. Luu, BS, A. Albekairy, PharmD., H. Yarandi, Ph.D., **T. Langaee, Ph.D.**, V. Freene, PA., S. Fujita, MD., W. Van der Werf, MD., A. Hemming, MD., R. Howard, MD., Ph.D., A. Reed, MD., J. Karlix, PharmD. Cytochrome P-450 3A4, 3A5, and MDR-1 As Pharmacogenomic Predictors of Tacrolimus Pharmacokinetics And Clinical Outcomes in Liver Transplant recipients. University of Florida, Gainesville, FL. Abstract was accepted by American Society for Clinical Pharmacology and Therapeutics(ASCPT) and

presented at the 2004 American Society for Clinical Pharmacology and Therapeutics Meeting, Miami Beach, FL, March 25, 2004.

Zineh I, Luo X, **Langaee TY**, Johnson JA, Chegini N. Th1- and Th2-related cytokine and chemokine balance in blood pressure responders and non-responders to metoprolol monotherapy. *Pharmacotherapy* 2004;24(10):1427.

Hruska MW, Cheong JA, Amico JA, **Langaee TY**, Frye RF. Effect of CYP2C8 Genotype on rosiglitazone pharmacokinetics. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and *Clin Pharmacol Ther* 2005; in press.

Hruska MW, Cheong JA, **Langaee TY**, Frye RF. Effect of St. John's Wort Administration on CYP2C8 Mediated Rosiglitazone Metabolism. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and *Clin Pharmacol Ther* 2005; in press.

B.S. Belgado, L.H. Cavallari, **T. Langaee**, T. Okorochukwu J. A. Johnson, PharmD. ASSOCIATION OF β 2-Adrenergic Receptor Haplotype and Hypertension in African-Americans and Caucasians. *Clin Pharmacol Ther* 2004;75(2):P95.

C. Formea, PharmD., T. Luu, BS, A. Albekairy, PharmD., H. Yarandi, Ph.D., **T. Langaee, Ph.D.**, V. Freene, PA., S. Fujita, MD., W. Van der Werf, MD., A. Hemming, MD., R. Howard, MD., Ph.D., A. Reed, MD., J. Karlix, PharmD. Cytochrome P-450 3A4, 3A5, and MDR-1 As Pharmacogenomic Predictors of Tacrolimus Pharmacokinetics And Clinical Outcomes in Liver Transplant recipients. *Clin Pharmacol Ther* 2004;75(2):P39.

Zineh I, Luo X, **Langaee TY**, Johnson JA, Chegini N. Th1- and Th2-related cytokine and chemokine balance in blood pressure responders and non-responders to metoprolol monotherapy. *Pharmacotherapy* 2004;24(10):1427.

Hruska MW, Cheong JA, Amico JA, **Langaee TY**, Frye RF. Effect of CYP2C8 Genotype on rosiglitazone pharmacokinetics. *Clin Pharmacol Ther* 2005;77(2):P36.

Hruska MW, Cheong JA, **Langaee TY**, Frye RF. Effect of St. John's Wort Administration on CYP2C8 Mediated Rosiglitazone Metabolism. *Clin Pharmacol Ther* 2005;77(2):P35.

Hudson AA, Zineh I, Yarandi HN, **Langaee TY**, Pauly DF, Johnson JA. Angiotensin system polymorphisms and traditional risk factors as predictors of heart failure prognosis. *Clin Pharmacol Ther* 2005;77(2):P63.

Gong Y, Beitelshes AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, **Langaee TY**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. BETA 2- ADRENERGIC RECEPTOR (B2AR) POLYMORPHISMS AND ANTIHYPERTENSIVE RESPONSE TO BETA-BLOCKER THERAPY IN THE INVEST TRIAL. *Clin Pharmacol Ther* 2005; 77 (2): P22.

Zineh I, **Langaee TY**, Welder GJ, Luo X, Arant CB, Wessel TR, Schofield RS, Chegini N. eNOS polymorphism is associated with early inflammation in normocholesterolemic patients. *Pharmacotherapy* 2005;25(3):473.

Zineh I, Arant CB, Wessel TR, **Langaee TY**, Welder GJ, Schofield RS. Apolipoprotein B/A ratio within the normal range is associated with elevated C-reactive protein in apparently healthy women. *Pharmacotherapy* 2005;25(3):453.

Hruska MW, Cheong JA, Amico JA, **Langaee TY**, Frye RF. Effect of CYP2C8 Genotype on rosiglitazone pharmacokinetics. *Clin Pharmacol Ther* 2005;77(2):P36.

Hruska MW, Cheong JA, **Langaee TY**, Frye RF. Effect of St. John's Wort Administration on CYP2C8 Mediated Rosiglitazone Metabolism. *Clin Pharmacol Ther* 2005;77(2):P35.

Hudson AA, Zineh I, Yarandi HN, **Langaee TY**, Pauly DF, Johnson JA. Angiotensin system polymorphisms and traditional risk factors as predictors of heart failure prognosis. Clin Pharmacol Ther 2005;77(2):P63.

Gong Y, Beitelshes AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, **Langaee TY**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. BETA 2- ADRENERGIC RECEPTOR (B2AR) POLYMORPHISMS AND ANTIHYPERTENSIVE RESPONSE TO BETA-BLOCKER THERAPY IN THE INVEST TRIAL. Clin Pharmacol Ther 2005; 77 (2): P22.

T.Y. Langaee, H.N. Yarandi, D. Katz, R.M. Dehoff, J.M. Kehoe, A.S. Klocman, C.J. Pepine, J.A. Johnson. DIFFERENCES IN VERAPAMIL RESPONSE BETWEEN CYP3A5 GENOTYPES. Clin Pharmacol Ther 2006;79(2):P12.

I. Zineh, **T.Y. Langaee**, T.R. Wessel, C.B. Arant, R.S. Schofield. Influence of SLCO1B1 (OATP1B/OATP-C) gene polymorphisms on cholesterol responses to Atorvastatin. Clin Pharmacol Ther 2006;79(2):P5.

M. Bruner, J.H. Karnes, Y. Gong, **T.Y. Langaee**, R.M. Cooper-Dehoff, C.J. Pepine, J.A. Johnson. Association of Angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with blood pressure response to ACE inhibitor in a subgroup of patients of the International Verapamil SR/Trandolapril Study (INVEST). Clin Pharmacol Ther 2006;79(2):P14.

D.L. Kroetz, Z. Yu, **T.Y. Langaee**, J.A. Johnson. Functionally significant variants of CYP2J2 and EPHX2 are not associated with hypertension. Clin Pharmacol Ther 2006;79(2):P15.

Y. Gong, A.L. Beitelshes, L.A. Stauffer, **T.Y. Langaee**, R.M. Cooper-Dehoff, C.J. Pepine, J.A. Johnson. Beta Adrenergic Receptors polymorphisms are associated with response to beta-blocker therapy in the International Verapamil SR/Trandolapril Study (INVEST). Clin Pharmacol Ther 2006;79(2):P130.

J. Shin, M.T. Lobbmeyer, Y. Gong, I. Zineh, **T.Y. Langaee**, H.N. Yarandi, D.F. Pauly, J.M. Aranda, R.S. Schofield, J.A. Hill, J.A. Johnson. A haplotype of Beta2- Adrenoceptor is associated with the increased risk for transplant or death in heart failure patients. Clin Pharmacol Ther 2006;79(2):P30.

J.A. Johnson, J.H. Karnes, M. Bruner, Y. Gong, **T.Y. Langaee**, R.M. Cooper-Dehoff, C.J. Pepine. Association of Lack of association of the Angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with cardiovascular and cerebrovascular outcomes in a subgroup of patients of the International Verapamil SR/Trandolapril Study (INVEST). Clin Pharmacol Ther 2006;79(2):P43.

I. Zineh, C.L. Aquilante, **T.Y. Langaee**, A. L. Beitelshes, T.R. Wessel, C.B. Arant, R.S. Schofield. Association of CXCL5 polymorphisms with plasma and leukocyte-produced epithelial neutrophil-activating peptide (ENA-78) concentrations. Clin Pharmacol Ther 2006;79(2):P59.

Pacanowski MA, Gong Y, **Langaee TY**, Cooper-DeHoff RM, Schork NJ, Pepine CJ, Johnson JA. β_2 -adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the International Verapamil SR/ trandolapril Study – GENETic Substudy (INVEST-GENES). [abstract] Clin Pharmacol Ther 2007;81(S1):S34. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 108th Annual Meeting, Anaheim, CA, March 2007.

T.Y. Langaee, B. Burkley, Y. Gong, I. Zineh. EFFECTS OF CYP3A4 AND CYP3A5 POLYMORPHISMS ON CHOLESTEROL RESPONSES TO ATORVASTATIN. [abstract] Clin Pharmacol Ther 2007;81(S1):S89. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 108th Annual Meeting, Anaheim, CA, March 2007.

Johnson AD, Gong Y, Wang D, **Langaee TY**, Shin J, Cooper-DeHoff RM, Schork NJ, Shriver MA, Binkley P, Pepine CJ, Johnson JA, Sadee W. Novel promoter polymorphisms in angiotensin-I converting enzyme (ACE) associated with clinical outcomes in hypertensive coronary artery disease (CAD) patients. Accepted for oral presentation at the American Society for Clinical Pharmacology and Therapeutics 109th Annual Meeting, Orlando, FL, March 2008.

H.A. Navare, A.L. Beitelshes, Pharm D, MPH, Y. Gong, PhD, **T.Y. Langaee, PhD**, R.M.Cooper-Dehoff, Pharm D, C.J.Pepine, MD, J.A.Johnson, Pharm D. *CACNA1C* POLYMORPHISMS AND CARDIOVASCULAR OUTCOMES IN THE INTERNATIONAL VERAPAMIL SR/TRANDOLAPRIL STUDY-GENETIC SUBSTUDY (INVEST-GENES). Accepted for poster presentation at the American Society for Clinical Pharmacology and Therapeutics 109th Annual Meeting, Orlando, FL, March 2008.

Mustafa Hassan, Kaki M. York, Haihong Li, Qin Li, Yan Gong, **Taimour Y. Langaee**, Roger B. Fillingim, Julie A. Johnson, David S. Sheps, University of Florida, Gainesville, FL. β 1-Adrenergic Receptor Polymorphism Predicts Mental Stress-induced Myocardial Ischemia in Patients with Coronary Artery Disease. Accepted at the American College of Cardiology 57th Annual Scientific Session, March 29-April 1, 2008, in Chicago, Illinois, USA. Additionally, this abstract has been nominated as a finalist in the "Best Poster Award Competition" at ACC.2008

Shristi Rawal, Margaret R. Wallace, John E. Hayes, Linda M. Bartoshuk, **Taimour Y. Langaee**, Andrew Sholudko, Valerie B. Duffy. TAS1R1-intronic SNP Associations with Liking for Dietary Sources of Glutamate and for Orosensory Intensity.2009.

Niu Y, **Langaee TY**, Gong Y, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. DNA variations in voltage-gated calcium channel beta2 subunit (*CACNB2*) gene, functional consequences and association with adverse cardiovascular outcomes in the International Verapamil SR-Trandolapril Study-Genetic Substudy. *Circulation*, Oct 2008;118: S_885. Poster presentation at the American Heart Association 2008 Scientific Sessions, New Orleans, LA, November 2008

Butler CP, Patel SR, **Langaee TY**, Nutescu EA, Shapiro NL, Cavallari LH. Apolipoprotein E genotype influences time to stable warfarin dosing. Poster presentation at the 2009 Annual Meeting of the American College of Clinical Pharmacy. Anaheim, CA. October 20, 2009.

**Second runner up in the Best Resident and Fellow Poster Competition.

Duarte JD, Tran B, **Langaee TY**, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Johnson JA. "YEATS4 Gene Region Polymorphisms Associate with Antihypertensive Response to Hydrochlorothiazide in African Americans." (Abstract) *Clinical Pharmacology and Therapeutics*, 2010 Feb;87(S1):S46

MJ Moore, VPW Chik, Y Gong, **T Langaee**, AB Chapman, GL Schwartz, ST Turner, JG Gums, RM Cooper-DeHoff, AL Beitelshes, JA Johnson. Association between melatonin receptor 1B single nucleotide polymorphisms (SNPs) and response to antihypertensive drugs. *Clin Pharmacol Ther*. 2010;87(1):S45. American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA, March 2010. [Poster and abstract, accepted]

Karnes JH, George AM, Gong Y, **Langaee TY**, Stauffer LA, Burkley BM, Pepine CJ, Johnson JA, Cooper-DeHoff RM. New onset diabetes risk associated with antihypertensive therapy in hypertensive coronary artery disease patients is modified by a single nucleotide polymorphism in the L-type calcium channel alpha 1c subunit (*CACNA1C*). *Clin Pharmacol Ther* 2010;87(S1):S45. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA. March 2010.

Stacpoole PW, Dunbar EM, Shroads AL, Coats BS, Langaee T. Predictability of glutathione transferase zeta 1 haplotype on kinetics of dichloroacetate in human trials. 10th International ISSX Meeting, Atlanta, GA, October 16-20, 2011.

Vandell AG, Lobmeyer MT, Gawronski B, **Langaee TY**, Gong Y, Beitelshes AL, Gums JG, Turner ST, Chapman AB, Cooper-DeHoff RM, Liggett SB, Johnson JA. INFLUENCE OF G PROTEIN RECEPTOR KINASE 4 (GRK4) POLYMORPHISMS ON BLOOD PRESSURE RESPONSE TO THE β -BLOCKER ATENOLOL. Presented at American Society of Clinical Pharmacology and Therapeutics 2011 Annual Meeting, Dallas TX, March 2011.

Vandell AG, Lobmeyer MT, Gawronski B, **Langaee TY**, Gong Y, Beitelshes AL, Gums JG, Turner ST, Chapman AB, Cooper-DeHoff RM, Liggett SB, Johnson JA. Influence of G Protein Receptor Kinase 4 (GRK4) Polymorphisms on Blood Pressure Response to the β -Blocker Atenolol. *Clinical Pharmacology & Therapeutics* (2011) 89, page S74.

JH Karnes, TT Vo, Y Gong, **TY Langaee**, AL Beitelshes, ST Turner, AB Chapman, JG Gums, K Bailey, E Boerwinkle, CJ Pepine, JA Johnson, and RM Cooper-DeHoff. KCNJ1 SNPs Are Associated With Increased Fasting Glucose And Risk of New Onset Diabetes During HCTZ Therapy. *Clin Pharmacol Ther* 2011;89(S1):S46

CW McDonough, B Burkely, Y Gong, **TY Langaee**, CJ Pepine, RM Cooper-DeHoff, JA Johnson. Non-synonymous SNPs in *SELE*, *SELP*, and *SIGLEC12* associate with Cardiovascular (CV) Outcomes in the International Verapamil SR-Trandolapril Study Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther*. 91 suppl 1: 2012, S20.

Gong Y, McDonough CW, Wang Z, Cooper-DeHoff RM, **Langaee TY**, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S16

Moore MJ, Gong Y, Schmidt S, Hall K, Chapman AB, **Langaee TY**, Gums JG, Coop-DeHoff RM, Johnson JA. Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose., *Clin Pharmacol Ther* 2012; 91 (S1): S25

Moore MJ, Gong Y, Hou W, Chapman AB, **Langaee TY**, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. Clinical Predictors of Dysglycemic Effects Associated with Use of Beta Blockers and Thiazide Diuretics. *Clin Pharmacol Ther*. 2012;91(1):S24-25.

Vandell AG, McDonough CW, **Langaee TY**, Burkley B, Gong Y, Turner ST, Gums JG, Chapman AB, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. Association of *FTO* with Hydrochlorothiazide (HCTZ)-induced elevation in uric acid (UA) in African American (AA) hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S59

Karnes JH, McDonough CW, Gong Y, **Langaee TY**, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Alpha adducin-1 (*ADD1*) single nucleotide polymorphism (SNP) associated with new onset diabetes risk with hydrochlorothiazide (HCTZ) therapy in the International Verapamil SR Trandolapril Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2012; 91 (S1): S21

Jianhua Liu, David Nessler, Amanda Eelsey, Alberto Riva, **Taimour Langaee**, Yang Li, Narayan Raum, Michael Conlon, Michael Clare-Salzler, Julie Johnson. Facilitating Genetic Testing for both Clinical Care and Research. The University of Florida Academic Health Center, Gainesville, FL. 2012

Gong Y, Moore MJ, Karnes JH, McDonough CW, Wang Z, **Langaee TY**, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Johnson JA, Coop-DeHoff RM. Fasting Glucose Loci Associated with Glucose Response to Antihypertensives-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). *Clin Pharmacol Ther* 2013; 93 (S1): S28

Minoli A Perera, Roxana Daneshjou, Eric R Gamazon, , Sara Hillenmeyer, Konrad Karczewski , Teri E Klein, **Taimour Langaee**, Kate Drozda, Shital Patel, Julie A Johnson , Larisa H Cavallari, Russ B Altman. Folylpolylglutamate synthetase (*FPGS*) and warfarin: discovery of genes outside of *CYP2C9* and *VKORC1* through exome analysis.2013.

Issam S. Hamadeh, **Taimour Y. Langaee**, Yan Gong, Ben M. Burkley, Todd C. Skaar, Julie A. Johnson. Impact of CYP2D6 polymorphisms on the clinical response & tolerability of metoprolol. University of Florida, Gainesville, FL; Emory University, Atlanta, GA; Mayo Clinic, Rochester, MN. Presented as a poster at ACCP meeting, USA, 2013.

Taimour Langaee, Caitrin W. McDonough, Larry Shroads, Peter Stacpoole, Margaret James. University of Florida, Gainesville, FL. Haplotype variations influence human *GSTZ1* gene expression and the kinetics of the anti-tumor drug dichloroacetate (DCA). Presented at ISSX meeting, Canada, 2013.

Gong Y, McDonough CW, Wang Z, **Langaee TY**, Beitelshes AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive

Responses Study. *Clin Pharmacol Ther* 2014; 95 (S1): S16. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.

Sa AC, Webb A, Gong Y, **Langaee T**, Turner S, Chapman A, Gums J, Scherer S, Cooper-DeHoff RM, SadeeW, Johnson JA. Identifying Genes Differentially Expressed Associated with Extreme Blood Pressure Response to Hydrochlorothiazide monotherapy. Abstract/Program 732M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014 in San Diego, CA.

Kawaguchi-Suzuki M, Bril F, Cusi K, **Langaee T**, Gong Y, Frye RF. Role of Genetic Polymorphisms on the Improvement of Liver Histology after Pioglitazone Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). *Hepatology* 2014;60(S1):591A. DOI: 10.1002/hep.27514.

S. Chang, Y. Gong, C.W. McDonough, N. Nasiri Kenari, **T. Langaee**, A.L. Beitelshes, J.G. Gums, A.B. Chapman, S.T. Turner, J.A. Johnson, R.M. Cooper-DeHoff. CORRELATING THE MELATONIN (MT) PATHWAY WITH ATENOLOL ASSOCIATED GLUCOSE DYSREGULATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY. (2015), Presidential Trainee Awards. *Clin. Pharmacol. Ther.*, 97: S17. doi:10.1002/cpt.48

M. H. Shahin, D. M. Rotroff, Y. Gong, **T. Langaee**, C. W. McDonough, A. L. Beitelshes, T. J. Garrett, A. B. Chapman, J. G. Gums, S. T. Turner, A. Motsinger-Reif, R. F. Frye, S. E. Scherer, W. Sadee, O. Fiehn, R. M. Cooper-DeHoff, R. Kaddurah-Daouk, J. A. Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. (2015), Presidential Trainee Awards. *Clinical Pharmacology & Therapeutics*, 97: S11–S18. doi: 10.1002/cpt.48.

M.H. Shahin, Y. Gong, **T. Langaee**, A.L. Beitelshes, D.M. Rotroff, A.B. Chapman, J.G. Gums, S.T. Turner, A. Motsinger-Reif, R.F. Frye, O. Fiehn, J.A. Johnson, R. Cooper-DeHoff, X. Han, R. Kaddurah-Daouk. Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2015, 97: S30.

Michelle M. Hwang, Hyun-Ji Choi **Taimour Y. Langaee**, Henrietta L. Logan and Kevin P. Raisch. Analysis of Saliva Samples from Healthy Adults in North Central Florida for Human Papillomavirus Infection. Presented at *American Association for Cancer Research Annual Meeting*, Philadelphia, PA. April. 18-22, 2015. Abstract no. 5585.

Mohamed H. Solayman^{1, 2}, **Taimour Langaee¹**, Yan Gong¹, Manal El-Hamamsy², Lamia El-Wakeel², Eric Boerwinkle³, Arlene Chapman⁴, Stephen Turner⁵, John Gums⁶, Amber Beitelshes⁷, Rhonda Cooper-DeHoff¹, Osama Badary², Julie Johnson¹. **Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers. (Student Award Winner, Podium Presentation)**. Published in Annual Meeting American College of Clinical Pharmacology September 27–29, 2015, San Francisco, CA, USA.

A. C. Sa, A. Webb, Y. Gong, C. W. McDonough, **T. Y. Langaee**, S. T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J. G. Gums, S. Scherer, R. M. Cooper-DeHoff, W. Sadee, J. A. Johnson. Molecular Markers of Blood Pressure Response to Thiazide Diuretics Identified Through Whole Transcriptome RNA-Seq Analysis, Program/Abstract #656. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.

M. H. Shahin , A. C. Sa , A. Webb , Y. Gong , **T. Langaee** , C. W. McDonough , A. L. Beitelshes , A. B. Chapman , J. G. Gums , S. T. Turner , R. F. Frye , S. E. Scherer , W. Sadee , R. M. Cooper-DeHoff , J. A. Johnson. Identifying a Novel Hypertension Genetic Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Program/Abstract #674. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.

Mohamed H Shahin, Daniel M Rotroff, Amy Webb, Yan Gong, **Taimour Langaee**, Caitrin W McDonough, Amber L Beitelshes, Timothy Garrett, John G Gums, Alison Motsinger-Reif, Arlene B Chapman, Stephen T Turner, Eric Boerwinkle, Reginald F Frye, Steven E Scherer, Wolfgang Sadee, Oliver Fiehn, Rhonda M Cooper-DeHoff, Rima

Kaddurah-Daouk, and Julie A Johnson. Circulation 2015;132:A13621. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 8, 2015. Orlando, FL.

A. C. Sa, A. Webb, Y. Gong, C.W. McDonough, M.H. Shahin, **T. Y. Langaee**, S.T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J.G. Gums, S. Scherer, R. M.Cooper-DeHoff, W. Sadee, J. A. Johnson. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. . Clinical Pharmacology & Therapeutics 2016, 99: S19 (PT23).

M. H. Shahin, A.C. Sa, A. Webb, Y. Gong, **T. Langaee**, C. W. McDonough, A. Riva, A. L. Beitelshes, A. B. Chapman, J. G. Gums, S. T. Turner, R. F. Frye, S. E. Scherer, W. Sadee, R. M. Cooper-DeHoff, J. A. Johnson. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. Clinical Pharmacology & Therapeutics 2016, 99: S19.

Naveen Mangal, Issam Hamadeh, Tanay Samant, **Taimour Langaee**, Larisa Cavallari, Julie Johnson, Jurgen Bulitta, Stephan Schmidt. Development of a CYP2C19 Genotype-Directed Bayesian Dosing Algorithm for Voriconazole.2016.

Meghan J. Arwood, Pharm.D., Caitrin W. McDonough, Ph.D., Larisa H. Cavallari, Pharm.D., Amanda R. Elsey, MHA, Reginald F. Frye, Pharm.D., Ph.D., Yan Gong, Ph.D., **Taimour Langaee, MSPH, Ph.D.**, Julie A. Johnson, Pharm.D., Kristin W. Weitzel, PharmD. Equipping health professional students to apply pharmacogenomic data to clinical decision making in real-world scenarios: Comparison of an active engagement versus didactic teaching approach. 2017.

Hoai Khanh Nguyen, Anita Szady, MD, Gloria Lipori, Qian Sun, Issam Hamadeh, PharmD, Rhonda M. Cooper-DeHoff, **Taimour Y. Langaee, PhD**, Chintan Shah, Carl J. Pepine, MD, Alexandra R. Lucas, MD, Jan Moreb, MD, Yan Gong, PhD. Cardiomyopathy Associated with Targeted Anticancer Drugs in Electronic Health Record. 2017.